Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 618-690-2 | CAS number: 90982-32-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- Deviations:
- yes
- Remarks:
- The tissue slides will be retained at the Haskell Laboratory for Toxicology and Industrial Medicine (Newark, Delaware) rather than at WIL. This protocol deviation has no effect on the study.
- GLP compliance:
- yes
Test material
- Reference substance name:
- ethyl 2-({[(4-chloro-6-methoxypyrimidin-2-yl)carbamoyl]amino}sulfonyl)benzoate
- EC Number:
- 618-690-2
- Cas Number:
- 90982-32-4
- Molecular formula:
- C15H15ClN4O6S
- IUPAC Name:
- ethyl 2-({[(4-chloro-6-methoxypyrimidin-2-yl)carbamoyl]amino}sulfonyl)benzoate
- Test material form:
- solid: particulate/powder
- Details on test material:
- Purity: 96.7%
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test animals: Source: Covance Research Products, Inc., Denver, Pennsylvania;
Age at study initiation: Approximately 15 weeks old;
Weight at study initiation: 2.3-2.7 kg (males) and 2.3-2.6 kg (females);
Housing: Animals were housed individually in clean, wire-mesh cages suspended above ground corn cob bedding (Bed-O'Cobs®);
Diet: PMI Feeds, Inc. Certified Rabbit LabDiet® 5322;
Water: Reverse osmosis-treated municipal water ad libitum;
Acclimation period: 9 Days;
Environmental conditions: Temperature: 68 ± 4°F and a relative humidity of approximately 30-70%; Photoperiod: 12-hour light/12-hour dark
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- water
- Details on exposure:
- 6 hours a day for 21 consecutive days
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 21 days
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day
- Dose / conc.:
- 400 mg/kg bw/day
- Dose / conc.:
- 1 000 mg/kg bw/day
- No. of animals per sex per dose:
- 5 males and 5 females
- Control animals:
- yes, concurrent vehicle
- Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- The animals were observed for signs of overt toxicity, dermal irritation and effects on body weight, food consumption and clinical pathologic (hematology and serum chemistry) parameters. Complete necropsies were performed on all animals. Selected organs were weighed. A microscopic examination was conducted on selected tissues from all animals in the control and 1000 mg/kg/day groups. In addition, the skin (treated and untreated), liver, lungs and kidneys from all animals in the 100 and 400 mg/kg/day groups were examined microscopically.
- Sacrifice and pathology:
- A complete necropsy was conducted on all animals. All animals were euthanized by an intravenous injection of sodium pentobarbital followed by exsanguination. The necropsies included, but were not limited to, examination of the external surface, all orifices, the cranial cavity, the external surfaces of the brain and spinal cord, and the thoracic, abdominal and pelvic cavities including viscera. The following tissues and organs were collected and placed in 10% neutral buffered formalin, except for eyes with optic nerve in Davidson's solution, and testes with epididymides in Bouin's solution: Adrenals (2), Aorta (thoracic), Bone with marrow (stemebrae), Brain (forebrain, mid-brain, hindbrain) Eyes with optic nerve (2), Gallbladder, Gastrointestinal tract, Esophagus, Stomach, Duodenum, Jejunum, Ileum, Cecum, Colon, Rectum, Heart, Kidneys (2), Liver (sections of two lobes), Lungs [including bronchi, fixed by inflation with fixative (2)], Lymph node (mesenteric and mandibular), Ovaries with oviducts (2), Pancreas, Parathyroids (if present), Peripheral nerve (sciatic), Pituitary, Prostate, Salivary gland [submaxillary (2)], Skeletal muscle (vastus medialis), Skin, dorsal (treated and untreated), Spinal cord (cervical, midthoracic and lumbar), Spleen, Testes with epididymides (2), Thymus, Thyroids, Trachea, Urinary bladder, Uterus with vagina, and All gross lesions.
- Statistics:
- All analyses were conducted using two-tailed tests for significance levels of 5% and 1% comparing the treatment groups to the vehicle control group by sex. All means are presented with standard deviations (S.D.) and the number of sampling units (N) used to calculate the means. All statistical tests were performed by a Digital® MicroVAX® 3400 computer with appropriate programming. Body weights, body weight changes, food consumption, clinical laboratory values and absolute and relative organ weights were analyzed by a one-way analysis of variance followed by Dunnett's Test. Clinical laboratory values for cell types that occur at a low incidence (i.e., monocytes, eosinophils and basophils) were not subjected to statistical analysis. The statistics for the microscopic evaluation were conducted by Haskell Laboratory, E. I. du Pont de Nemours and Company.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance-related clinical findings were noted at any dose level. Clinical signs observed in the treated groups (such as soft feces, wet or dried yellow or brown material in the urogenital region, red ocular discharge, etc.) were observed at low incidence, were not present in a dose-related manner and/or were not uncommon findings in laboratory rabbits. Occasional red or yellow material observed around the mouth of some animals was noted in conjunction with the Elizabethan restraint collar found caught in the animal's mouth.
- Dermal irritation:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance-related dermal irritation was observed in any treatment groups. Very slight erythema was occasionally noted for 1, 1, 5 and 4 males and 2, 3, 1 and 2 females in the control, 100, 400 and 1000 mg/kg/day groups, respectively. On single occasions, one 400 mg/kg/day group male (no. 22330) exhibited slight erythema and one 1000 mg/kg/day group female (no. 22339) exhibited very slight erythema with very slight edema. This female and one control group female (no. 22357) also had single occurrences of desquamation. The limited occurrence of the dermal findings in all groups, including the control, suggests that the irritation was probably a result of the procedures used to remove the test substance rather than a test substance-related effect.
- Mortality:
- not specified
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No test substance-related effects on mean body weights or body weight gains were observed. Values in the treated groups were comparable to the control group values throughout the study.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No test substance-related effects on food consumption were observed. Food consumption in the treated groups was similar to the control group throughout the study.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- Food efficiency reflected body weight values throughout the study.
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Alkaline phosphatase was increased in the 100 mg/kg/day group males. Albumin was decreased in the 400 mg/kg/day group females and aspartate aminotransferase was decreased in the 100 mg/kg/day group females and in the 400 mg/kg/day group males and females. These changes were not considered to be compound related as the differences were not large, were not observed in a dose-related manner and/or treatment period values were similar to pretest values.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Organ weights (absolute and relative to final body weight) were unaffected by treatment. Mean absolute adrenal gland weights and adrenal gland weights relative to final body weight ratios were increased in the 400 and 1000 mg/kg/day group females at the scheduled necropsy. The differences from the control group were statistically significant at p<0.01 and p<0.05, respectively. However, these increases were not considered to be test substance-related as the differences from control group values did not occur in a dose-related manner and similar changes were not observed in the males.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test substance-related gross lesions, noted at the macroscopic examination. Findings present in the treated groups (dark red lungs, reddened thyroid glands or trachea, cystic oviducts, accessory spleens) occurred similarly in the control group, were limited to single animals and/or were findings commonly observed in laboratory rabbits.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Microscopic examination revealed no test substance-related changes. Fatty change and regeneration of renal tubules, noted for one female from the 1000 mg/kg day group (no. 22343), were the result of protozoan infection. All other findings were considered incidental (dermal, pulmonary, cardiac or liver inflammation, liver necrosis, thyroid hyperplasia, etc.) or findings commonly noted in laboratory rabbits (accessory spleen, cystic oviducts, testicular atrophy, etc.)
- Histopathological findings: neoplastic:
- not examined
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- In a 21-day dermal study in rabbits, there were no test substance effects at the highest dose tested, 1000 mg/kg/day.
- Executive summary:
OECD Test Guideline 410 - The test substance was applied seven days per week for three consecutive weeks to the shaved intact dorsal skin of each rabbit for a minimum of 21 applications. The application sites were wrapped for six hours with a gauze dressing, which was covered with impervious plastic wrap and secured with Dennifonn® tape. Each of the three test substance-treated groups consisted of five males and five females. Dosage levels of 100, 400 and 1000 mg/kg/day were selected for the study. A concurrent control group of identical design received 5.0 mL/animal/day of deionized water on a comparable regimen. All animals, wore Elizabethan collars during the six-hour exposure period. Residual test substance was removed from the application sites with Ivory® soap, warm tap water and wet paper towels following the six-hour exposure period. The animals were observed for signs of overt toxicity, dermal irritation and effects on body weight, food consumption and clinical pathologic (hematology and serum chemistry) parameters. Complete necropsies were performed on all animals. Selected organs were weighed. A microscopic examination was conducted on selected tissues from all animals in the control and 1000 mg/kg/day groups. In addition, the skin (treated and untreated), liver, lungs and kidneys from all animals in the 100 and 400 mg/kg/day groups were examined microscopically.
There were no test substance-related effects on the clinical condition of the rabbits. Food consumption, food efficiency and body weight data were unaffected by treatment with the test substance. Test substance administration had no effect on hematology and serum chemistry parameters or organ weight data. There were no test substance-related lesions noted at the macroscopic or microscopic examinations. Under the conditions of this study, the no-observed-effect level (NOEL) is defined as the highest dose at which toxicologically important effects attributable to the test substance were not detected. Thus, for this study, the NOEL is equivalet to the NOEL as defined by the U.S. EPA and the no-observed-adverse-effect-level (NOAEL) as defined by the European Union. The NOEL for toxicity for this study was 1000 mg/kg/day, the highest dose tested for both male and female rabbits.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.